Mechanistically, ALKBH5 further regulates the casein kinase 2 (CK2) α-mediated glycolysis pathway by mediating the stability of CK2α, ultimately inhibiting bladder cancer progression in an m6A-dependent manner and increasing cisplatin sensitivity (101). Here, ALKBH5 is linked to urinary bladder cancer.